hoops I thought I would ask ChatGpt your question, so

New Post Public Reply Private Reply Replies (1) Message Board
biloxiblues hoops #153779
631
hoops

I thought I would ask ChatGpt your question, so here is her reply. I know that we have one member of our group who does not like her, but here you go,

Your question gets right to the heart of the current tension around CytoDyn’s strategy, and it’s a smart observation. Let’s unpack the most likely reasons for the company attending ESMO Breast Cancer in Berlin but not ASCO in Chicago, despite the perception that ASCO carries more global prestige.

1. Strategic Targeting: ESMO Breast Cancer was More Focused
ESMO Breast Cancer 2024 was specifically focused on breast cancer, including mTNBC, whereas ASCO has a broader oncology scope and is more competitive for attention.

The poster presentation at ESMO gave CytoDyn a relatively high-visibility platform in a focused, relevant audience—mostly breast cancer specialists and European oncologists—without being drowned out by hundreds of presentations.

TNBC emphasis was significant at ESMO: multiple sessions addressed immunotherapy, PD-L1, ADCs, and metastatic TNBC. That’s ideal terrain for presenting the survival data CytoDyn just published.

2. Europe as a Regulatory Foothold
The fact that they “loaded the plane” implies a substantial team effort, likely including meetings with European regulatory consultants or potential partners.

EMA (European Medicines Agency) may be viewed as less politically entangled than the current FDA. If management believes the FDA is still unreceptive (or tainted by past disputes), pursuing EMA first could offer:

A faster path to approval via compassionate use or orphan designation.

Leverage for FDA reconsideration once European validation exists.

Leronlimab’s clean safety profile and immunomodulatory mechanism could appeal more to European regulators, who often favor immune restoration and quality-of-life metrics.

3. Management Skepticism Toward the FDA
Your speculation that CytoDyn may lack confidence in the FDA is reasonable. The company’s history with the FDA—rejected BLA filings, disputes over trial design, and the ongoing fallout from prior leadership—suggests lingering mistrust.

Attending ASCO would have raised visibility with the U.S. oncology establishment, which may include critics or skeptics still influenced by the old narrative around CytoDyn.

By contrast, ESMO was a cleaner slate—an opportunity to reset impressions with an international audience.

4. Logistics, Cost, and Focus
ASCO is expensive. CytoDyn is financially constrained. Unless you have a late-breaking abstract or a major Phase 3 study, it’s hard to stand out at ASCO.

ESMO was a better fit for the early-but-promising survival data and allowed for one-on-one meetings with key opinion leaders and pharma representatives in a more intimate setting.

Bottom Line
It’s likely a mix of:

Targeting a more relevant and receptive audience (ESMO Breast Cancer).

Sending signals of a pivot to European regulatory pathways (EMA).

Avoiding political or institutional baggage with the FDA and ASCO.

Resource constraints and return-on-investment calculations.

They may be laying the groundwork for an EMA submission, partnership, or follow-on trials in Europe, which might eventually back-pressure the FDA into action. If EMA gives leronlimab a serious look, that becomes a powerful narrative turnaround.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 21

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 66

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
Corner Bakery Bets on Holiday Catering Convenience

Updated Category News Views 150

A $50 carrot on a $350 catering tab tells you exactly where Corner Bakery sees the holiday battlefield: not in one lonely cookie sale, but in the larger group order that can make a restaurant’s day. The chain is pushing holiday catering through November and December, pairing that discount with bakery trays, meals for groups and a promise to handle delivery setup. It is...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 7

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 135

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 95

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 38

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 180

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 65

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 110

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading

Top 5 Most Recently Viewed Articles

Pharvaris Shares Promising Data on Deucrictibant Efficacy

Updated Category News Views 186

Pharvaris Highlights Clinical Progress in HAE Treatment At the recent AAAAI/WAO Joint Congress, Pharvaris presented compelling long-term clinical data supporting the use of deucrictibant, a novel oral treatment for hereditary angioedema (HAE). This data underscores the drug's potential to not only prevent but also effectively address HAE attacks, offering hope to those...

Continue Reading
First Horizon Opens New Banking Center Celebrating Local Pride

Updated Category News Views 349

First Horizon Unveils New Banking Center with Appalachian Spirit First Horizon Bank (NYSE: FHN) proudly celebrated the grand opening of its newly refreshed banking center. The location pays tribute to the vibrant Appalachian State community, showcasing a striking theme that reflects its strong ties with Appalachian State University and its athletics. This celebration...

Continue Reading
Understanding Namodenoson's Role in Liver Cancer and Beyond

Updated Category News Views 243

Innovative Research on Namodenoson’s Impact in Liver Cancer Therapy Namodenoson, developed by Can-Fite BioPharma Ltd., is making waves in the medical community as a promising candidate for liver cancer treatment. Unlike traditional chemotherapy, which often harms healthy cells, Namodenoson is lauded for its protective qualities towards normal body systems. Published...

Continue Reading
Geotab Enhances Public Sector Solutions with Technological Advancements

Updated Category News Views 147

Geotab Enhances Public Sector Solutions with Technological Advancements Geotab Inc., a leader in connected vehicle solutions and asset management, has taken a major step forward in serving the public sector by expanding its cooperative purchasing contracts with Sourcewell and Canoe Procurement Group. This expansion introduces four cutting-edge solutions aimed at enhancing...

Continue Reading
Dun & Bradstreet Earns TRUSTe Certification for Responsible AI

Updated Category News Views 351

Dun & Bradstreet Achieves TRUSTe Responsible AI Certification Dun & Bradstreet (NYSE:DNB), recognized globally as a leading provider of business decisioning data and analytics, has been awarded the TRUSTe Responsible AI Certification. This certification signifies the company’s commitment to ethical and responsible governance in the realm of artificial intelligence (AI)....

Continue Reading